Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences director Leslie V. Norwalk reported trades in company stock. On July 28, 2026, she sold 1,250 common shares at a weighted-average price of $182.006 per share in multiple open-market transactions executed pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025, with issuer policy restricting later plan modifications. On July 29, 2026, she exercised Non-Qualified Stock Options to acquire 842 common shares at an exercise price of $139.43 per share, leaving 2,140 options from that grant outstanding, which expire on May 22, 2034.
Neurocrine Biosciences reported strong second-quarter 2026 results. Total revenues were $959 million, a 39% year-over-year increase, driven by INGREZZA net product sales of $716 million, CRENESSITY sales of $184 million and initial VYKAT XR sales of $54 million following the May 18 closing of the Soleno Therapeutics acquisition. Unaudited pro-forma total revenue, including a full quarter of VYKAT XR, was $998 million.
GAAP net income for the quarter was $144 million, or $1.39 per diluted share, while Non-GAAP net income was $297 million, or $2.85 per diluted share. The company raised 2026 INGREZZA net sales guidance to $2.825–$2.875 billion. Neurocrine completed the $2.9 billion Soleno acquisition, recorded approximately $2.2 billion of VYKAT XR-related intangible assets, and ended June 30, 2026 with about $482 million in cash, cash equivalents and marketable securities plus an undrawn $1.0 billion senior secured revolving credit facility to support ongoing R&D and commercial investments.
JPMorgan Chase & Co. filed an amended Schedule 13G reporting its beneficial ownership in Neurocrine Biosciences, Inc. common stock. JPMorgan reports beneficial ownership of 6,338,240 shares, representing 6.3% of the class of Neurocrine’s common stock, $0.001 par value.
Within this position, JPMorgan has sole voting powershared voting powersole dispositive powershared dispositive power
Neurocrine Biosciences Inc. Chief Regulatory Officer Ingrid Delaet reported an exercise-and-sale sequence in company stock. She exercised options to acquire 4,367 shares of common stock at $106.02 per share and, on the same date, sold 4,367 shares in open-market transactions at an average price of $181.02 per share. Following these transactions, she held 20,592 shares of common stock directly in one non-derivative holding and 16,225 shares in another reported line. The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, and the exercised options were originally granted in 2021 with a vesting schedule through 2025.
Neurocrine Biosciences Inc. Chief Legal Officer Darin Lippoldt reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025, with individual trade prices ranging from $179.50 to $179.80.
On the same date, Lippoldt also exercised non-qualified stock options covering 10,000 shares of common stock at an exercise price of $81.49 per share, reducing the reported option balance to 4,965 options on this grant. These options were granted on February 5, 2018, vested in 48 equal monthly installments beginning March 5, 2018, and are scheduled to expire on February 5, 2028.
Neurocrine Biosciences (NBIX) reports that an affiliate through Morgan Stanley Smith Barney LLC’s Executive Financial Services plans to sell 4,367 shares of common stock on 07/10/2026, in connection with an Exercise of Stock Options for cash. The planned sale reflects an indicated value of 788,461.85. In the prior three months, Ingrid Delaet completed multiple Rule 10b5-1 sales of NBIX common stock, including 8,433 shares on 07/09/2026 for 1,507,134.80 and additional sales on 07/08/2026, 07/07/2026, and 05/29/2026.
Neurocrine Biosciences Chief Regulatory Officer Ingrid Delaet reported a series of option exercises and related stock sales in early July. She exercised stock options covering 14,571 shares of common stock at an exercise price of $103.52 per share, then sold an equal number of shares in open-market transactions at weighted average prices around $178.55–$178.72 per share.
The transactions on July 7–9, 2026 were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following these trades, Delaet directly owns 16,225 shares of Neurocrine Biosciences common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for the proposed sale of 10,000 shares of Common Stock tied to an exercise of stock options with an execution method listed as cash and a filing date of 07/09/2026. The excerpt also lists recent 10b5-1 sales by Darin Lippoldt totaling 9,800 shares on 06/29/2026 for $1,667,578.78 and 200 shares on 06/26/2026 for $33,913.00. The content shows 100,549,983 shares outstanding as of 07/09/2026.
The filing reports insider transactions by an individual identified as Ingrid Delaet. It shows an exercise of stock options resulting in 14,571 shares on 07/07/2026 (cash exercise) and prior 10b5-1 sales of 2,261 shares on 05/29/2026 for $354,321.31.